Adaptive study of the dose of the drug aldesleukin (interleukin-2) on regulatory T cells in type 1diabetes (DILT1D)
Dr Frank Waldron-Lynch
Institution or company
University of Cambridge
Type 1 diabetes is an autoimmune condition.
The immune system (the body's natural defence against infection and illness) mistakes the cells in your pancreas as harmful and attacks them, destroying them completely or damaging them enough to stop them producing insulin.
This trial is using a drug -aldesleukin (interleukin-2) -that at low doses resets the immune system, to see if the destructive process can be halted in people with newly diagnosed type 1 diabetes, and if so, to determine the dose needed to do that.